Title: Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy
to surgery is related to unimproved pathological response and poor survival prognosis for
esophageal squamous cell carcinoma
Version: 1 Date: 28 Dec 2024
Reviewer:  Katsushi Takebayashi
Reviewer's report:
Comments to the Author
Thank you for letting me review this interesting article.
This study is conducted by the patients with esophageal squamous cell carcinoma
patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by
esophagectomy. Prolonged time interval from neoadjuvant immunotherapy to surgery was
associated with worse clinical outcome. I also consider esophageal cancer patients should avoid
delaying surgery after neoadjuvant chemotherapy because of local tumor progression. However,
I have some questions around the methodology around your study.
1. What is the reason of prolonged interval from neoadjuvant immunotherapy to surgery? This
matter may affect clinical outcomes. Especially, please show the reason of delaying surgery after
neoadjuvant chemotherapy clearly.
2. The authors set the cut-off point of 6 weeks. They used its point by most clinical trials. I
also feel it may lead to potential bias. Generally, the interval time from neoadjuvant therapy
to surgery is in 4 to 8 weeks. Is it reasonable to divide esophageal cancer patients into groups
of 8 weeks or more, as an analysis? Did the authors consider additional evaluation about time
interval?
Title: Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy
to surgery is related to unimproved pathological response and poor survival prognosis for
esophageal squamous cell carcinoma
Version: 1 Date: 28 Dec 2024
Reviewer:  Katsushi Takebayashi
Reviewer's report:
Comments to the Author
Thank you for letting me review this interesting article.
This study is conducted by the patients with esophageal squamous cell carcinoma
patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by
esophagectomy. Prolonged time interval from neoadjuvant immunotherapy to surgery was
associated with worse clinical outcome. I also consider esophageal cancer patients should avoid
delaying surgery after neoadjuvant chemotherapy because of local tumor progression. However,
I have some questions around the methodology around your study.
1. What is the reason of prolonged interval from neoadjuvant immunotherapy to surgery? This
matter may affect clinical outcomes. Especially, please show the reason of delaying surgery after
neoadjuvant chemotherapy clearly.
2. The authors set the cut-off point of 6 weeks. They used its point by most clinical trials. I
also feel it may lead to potential bias. Generally, the interval time from neoadjuvant therapy
to surgery is in 4 to 8 weeks. Is it reasonable to divide esophageal cancer patients into groups
of 8 weeks or more, as an analysis? Did the authors consider additional evaluation about time
interval?
Please review this paper.
user
Title: Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy
to surgery is related to unimproved pathological response and poor survival prognosis for
esophageal squamous cell carcinoma
Version: 1 Date: 28 Dec 2024
Reviewer:  Katsushi Takebayashi
Reviewer's report:
Comments to the Author
Thank you for letting me review this interesting article.
This study is conducted by the patients with esophageal squamous cell carcinoma
patients receiving neoadjuvant immunotherapy combined with chemotherapy followed by
esophagectomy. Prolonged time interval from neoadjuvant immunotherapy to surgery was
associated with worse clinical outcome. I also consider esophageal cancer patients should avoid
delaying surgery after neoadjuvant chemotherapy because of local tumor progression. However,
I have some questions around the methodology around your study.
1. What is the reason of prolonged interval from neoadjuvant immunotherapy to surgery? This
matter may affect clinical outcomes. Especially, please show the reason of delaying surgery after
neoadjuvant chemotherapy clearly.
2. The authors set the cut-off point of 6 weeks. They used its point by most clinical trials. I
also feel it may lead to potential bias. Generally, the interval time from neoadjuvant therapy
to surgery is in 4 to 8 weeks. Is it reasonable to divide esophageal cancer patients into groups
of 8 weeks or more, as an analysis? Did the authors consider additional evaluation about time
interval?
assistant